Systematic Review and Network Meta-Analysis on Treating Hormone Receptor-Positive Metastatic Breast Cancer After CDK4/6 Inhibitors

Introduction: The optimal treatment of estrogen receptor-positive (ER +) metastatic breast cancer (MBC) after progression on cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) is unknown. Methods: We conducted a systematic review and network meta-analysis (NMA) of phase-II/-III randomized trials of ER...

Cijeli opis

Bibliografski detalji

Glavni autori:	Neha Pathak, Abhenil Mittal, Sudhir Kumar, Chitrakshi Nagpal, Eitan Amir, Partha Haldar, Bharath B. Gangadharaiah, Akash Kumar, Ashutosh Mishra, Atul Batra
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2025-01-01
Serija:	Current Oncology
Teme:	metastatic breast cancer CDK4/6 inhibitor hormone receptor-positive cancer SERD HER2-low breast cancer AKT inhibitor
Online pristup:	https://www.mdpi.com/1718-7729/32/1/53
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!